MetaCap

Nuvectis Pharma (NVCT) vs Olema Oncology (OLMA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Nuvectis Pharma (NVCT) has outperformed Olema Oncology (OLMA) over the past year, gaining 218.9% versus a loss of 69.7%. Nuvectis Pharma is the larger company by market cap ($666.8 million vs $615.0 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

NVCT+218.91%OLMA-69.70%
+391%+148%-94%
Nov 21, 20251 yearNov 20, 2026
NVCT+496.62%OLMA+19.39%
+777%+337%-103%
Jan 31, 20225 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

NVCT versus OLMA key metrics
MetricNVCTOLMA
Share price$19.39$7.02
Market cap$666.80M$615.00M
1-day change-2.27%-1.82%
YTD return+156.82%-71.92%
1-year return+218.91%-69.70%
5-year return—-66.36%
EPS (TTM)$-2.00$-2.40
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-26.44M$-162.45M
52-week high$29.28$36.26
52-week low$5.77$6.24
Distance from 52-week high-33.77%-80.64%
Analyst consensusnonestrong_buy
Avg. price target upside+82.57%+405.70%
Average volume206.37K1.27M
Shares outstanding34.39M87.61M
Employees19131
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • NVCT has outperformed OLMA by 288.6 percentage points over the past year.

About Nuvectis Pharma

NVCT stock →

Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors.

Health Care · Biotechnology: Pharmaceutical Preparations · 19 employees

About Olema Oncology

OLMA stock →

Olema Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for breast cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic ER-positive, human epidermal growth factor receptor 2-negative breast cancer; OPERA-01, the pivotal Phase 3 clinical trial of palazestrant as a monotherapy in second/third-line ER+/HER2- metastatic breast cancer; and palazestrant with CDK4/6 inhibitors, a phosphatidylinositol 3 kinase alpha (PI3Ka) inhibitor alpelisib, a mechanistic target of rapamycin inhibitor, and a CDK4 inhibitor that is in Phase 1b/2 clinical trial for the treatment of ER+/HER2- advanced or metastatic breast cancer.

Health Care · Biotechnology: Pharmaceutical Preparations · 131 employees

NVCT vs OLMA FAQ

Which is bigger, Nuvectis Pharma or Olema Oncology?

Nuvectis Pharma (NVCT) is larger, with a market capitalization of $666.80M compared with $615.00M for Olema Oncology (OLMA).

Which stock has performed better over the past year, NVCT or OLMA?

NVCT returned +218.91% over the past 12 months, compared with -69.70% for OLMA (price return, excluding dividends). Past performance does not predict future results.

Are Nuvectis Pharma and Olema Oncology in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons